Scott Donaldson

Has grant

Professor of Medicine

University of North Carolina at Chapel Hill

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Development of Novel Mycolytic Therapies for Lung Disease

Open Date: 2012-06-15

Close Date: 2022-06-30

Grant: Close

SCCOR in Host Factors in Chronic Lung Disease

Open Date: 2006-09-15

Close Date: 2012-07-31

Grant: Close

UNC Cystic Fibrosis Research and Translation Core Center

Open Date: 2004-04-01

Close Date: 2020-03-31

Grant: Close

Regulation of ENaC by Serine Proteases in Airways

Open Date: 2002-05-16

Close Date: 2007-04-30

Grant: Close

General Clinical Research Center

Open Date: 1974-10-01

Close Date: 2008-05-31

Articles (12)

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

Deborah Gill

Professor of Gene Medicine

University of Oxford Radcliffe Department of Medicine

UNITED KINGDOM

View details

Brian Soher

Associate Professor

Duke University Medical Center

UNITED STATES

View details

LUCAS HOFFMAN

Professor and Vice Chair

University of Washington

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Scott Donaldson

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (12)

Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-In-Human Trial

Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study

More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Current state of CFTR modulators for treatment of Cystic Fibrosis

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis

Effect of lumacaftor-ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis: Results from the PROSPECT MCC sub-study

Dynamic perfluorinated gas MRI reveals abnormal ventilation despite normal FEV1 in cystic fibrosis.

A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes

Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study

Collaborators (3)

Deborah Gill

Brian Soher

LUCAS HOFFMAN

Make your next move.